Table 3.

Onset of audio-vestibular symptoms following SARS-CoV-2 infection and COVID-19 vaccination.

	SARS-CoV-2 infection			COVID-19 vaccine
	Onset within 2 weeks N (%)	Onset between 2 and 4 weeks N (%)	N (total)	Onset within a week of the 1st dose N (%)	Onset within a week of the 2nd dose N (%)	Onset within a week of the 1st and 2nd dose N (%)	N (total)
Tinnitus	9 (81.8 %)	2 (18.2 %)	11	1 (50 %)	0 (0 %)	1 (50 %)	2
Hyperacusis	14 (93.3 %)	1 (6.7 %)	15	2 (66.7 %)	1 (33.3 %)	0 (0 %)	3
Aural fullness	31 (93.9 %)	2 (6.1 %)	33	1 (25 %)	1 (25 %)	2 (50 %)	4
Otalgia	21 (91.3 %)	2 (8.7 %)	23	0 (0 %)	0 (0 %)	0 (0 %)	0
Otorrhea	11 (100 %)	0 (0 %)	11	0 (0 %)	0 (0 %)	0 (0 %)	0
Vertigo	1 (14.3 %)	6 (85.7 %)	7	0 (0 %)	0 (0 %)	0 (0 %)	0
Dizziness	7 (77.8.%)	2 (22.2 %)	9	1 (20 %)	1 (20 %)	3 (60 %)	5